Navigation Links
Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
Date:1/17/2008

MONTVALE, N.J., Jan. 17 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (Amex: SYI) today announced the signing of an agreement with privately- held Novel Therapeutic Technologies, Inc. to provide Synvista with formulation work for a topical cream formulation of ALT-2074 for the treatment of psoriasis. ALT-2074 is one of the Company's lead compounds under development for use in cardiovascular disease.

"We believe that ALT-2074 is a logical choice for a potential therapy in mild-to-moderate plaque psoriasis. TNF-alpha is an established target for drug development in psoriasis and other autoimmune diseases. The effectiveness of approved TNF antagonists may relate to their demonstrated ability to inhibit the induction of cell adhesion molecules and consequent migration of pro-inflammatory cells into inflamed tissue," said Noah Berkowitz, M.D., Ph.D., President and Chief Executive Officer of Synvista Therapeutics. "ALT-2074 can block TNF-alpha activated expression of cell adhesion molecules, I-CAM and V-CAM, which may be essential for cellular migration. As such, we believe that a topical formulation of ALT-2074 may be a promising therapy for mild-to-moderate plaque psoriasis, without the side effects associated with systemic treatment using anti-TNF biologics."

"We have identified sites in Israel to perform a planned Phase 2 clinical trial for plaque psoriasis beginning mid-2008, pending approval from the Ministry of Health in Israel," added Dr. Berkowitz. "The Ministry of Health is already familiar with ALT-2074 since it approved its use in our ongoing Study 203. Based on our current timeline, assuming timely receipt of regulatory approval, we hope to announce study results in the fourth quarter of 2008. We expect this ps
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Synvista Therapeutics to be Featured on Wallst.net
2. Synvista Therapeutics to Present at the BIO InvestorForum 2007
3. Cell Therapeutics, Inc. (CTI) Prices $1.27 million (euros 856.000) Offering of Common Stock through Societe Generale
4. Protalix BioTherapeutics Signs Lease Agreement for Expansion of its Manufacturing and Research Facility in Carmiel, Israel
5. Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus
6. Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors
7. Nektar Therapeutics President and CEO Howard W. Robin to Present At JPMorgan 26th Annual Healthcare Conference
8. Cell Therapeutics, Inc. (CTI) Hosts Conference Call to Discuss Update on Zevalin(R) Acquisition, CMS Reimbursement, and PIX301 Timeline
9. Sirnaomics Received Multiple Government Fundings For Its Multi-Targeted siRNA Therapeutics Programs
10. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
11. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013  Rahal Letterman Lanigan ... human cord blood stem cell banking and therapeutics, announced ... the No. 16 Acorn Stairlifts Indy car driven by ... the remainder of the IZOD IndyCar 2013 season.   ... will work to support awareness of umbilical cord blood ...
(Date:5/23/2013)... , May 23, 2013 VG ... strategic alliance with DAK Renewable Research to conduct ... oil yield. VG Energy is a majority owned ... VGLS). VG Energy,s exclusively licensed compound ... the oil yield in plants, possessing a wide ...
(Date:5/23/2013)... , May 23, 2013 BioTrends Research ... advisory firms for specialized biopharmaceutical issues, finds that, ... infectious disease specialists reported that in the past ... intentionally delaying treatment) in anticipation of the next ... months ago, when only 6 percent reported that ...
(Date:5/23/2013)... Md. , May 23, 2013 Northwest ... biotechnology company developing DCVax ® personalized immune therapies ... use its exhibit at this year,s American Society Of ... to highlight its leadership role in immune therapy.  ... The ASCO annual meeting is the pre-eminent conference focused ...
Breaking Biology Technology:StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3
... molecules that appear in the central region of ,macromolecules ... atom ,at their center that determines their specific function. ... molecular electronics lies in their "ease of transfer ,electrons ... the work at the Nanomaterials and Nanotechnology Research Center ...
... Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced today that ... Friday, September 9, 2011 at 10:55 a.m. EDT (7:55 a.m. ... Hotel in Boston.  Steve Worland, Ph.D., President and Chief Executive ... its clinical development programs, setrobuvir and ANA773. Dr. ...
... (NYSE Amex: CUR ) announced that President ... Stifel Nicolaus Annual Healthcare Conference on Wednesday, September 7 ... opportunities and advancements in neural stem cell pharmaceuticals and ... the ongoing ALS trial at Emory University. ...
Cached Biology Technology:The quantum tunneling effect leads electron transport in porphyrins 2Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences 2Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences 3Neuralstem President and CEO to Present at the 2011 Stifel Nicolaus Annual Healthcare Conference 2Neuralstem President and CEO to Present at the 2011 Stifel Nicolaus Annual Healthcare Conference 3
(Date:5/24/2013)... 500 leading water scientists from around the world today ... the short span of one or two generations, the ... be living under the handicap of severe pressure on ... there is no substitute. This handicap will be self-inflicted ... bluntly pointed to chronic underlying problems led by mismanagement ...
(Date:5/23/2013)... , Automated conserved noncoding sequence (CNS) ... among grasses , Within the genome of each ... undergo little change in position and sequence over millions ... Some of these evolutionarily stable sequences, so-called conserved noncoding ... other genes or the condensation of chromosomes, but the ...
(Date:5/23/2013)... world,s most popular fruit, can be made both better-tasting ... varieties. , "Working with GM tomatoes that are ... a specific compound, allows us to pinpoint exactly how ... from the John Innes Centre. , The research could ... and shelf life characteristics because even higher levels of ...
Breaking Biology News(10 mins):A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 2A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 3A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 4Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3The world's favorite fruit only better-tasting and longer-lasting 2
... jumps out of the bushes, youre still surprised. But your ... have begun to distinguish the circuitry in the brains emotion ... aversive or reward valence of a stimulus. C. Daniel ... 2007 issue of the journal Neuron, published by Cell Press. ...
... trenches in the First World War, but nearly a century ... discovered that phosgene is present in significant quantities in the ... well after the Second World War, but its continued presence ... used in the chemical industry. A team, including ...
... emissions should quickly reduce mercury levels in lake fish, ... the Proceedings of the National Academy of Science. The ... rates relevant to atmospheric deposition resulted in a significant ... only three years. This is good news. ...
Cached Biology News:How the brain handles surprise, good and bad 2Scientists in first global study of 'poison' gas in the atmosphere 2New study shows fish respond quickly to changes in mercury deposition 2New study shows fish respond quickly to changes in mercury deposition 3
...
SHEEP ANTI ESCHERICHIA COLI...
RayBio Human Chemokine Antibody Array 1.1 (8) with Accessory, detects 38 chemokine factors (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
... Multi-Sample Freezing-point Osmometer for 30 L samples, featuring 24-position turntable. Provides up to 30 minutes ... and software for statistical analysis and record keeping. RS-232 port. ... ... ...
Biology Products: